MannKind | MNKD - Umsatzkosten





Umsatzkosten Veränderung Datum
Adma Biologics USD 50.4M 8.24M 2025-12
BioCryst Pharmaceuticals USD 9.52M 7.34M 2025-12
Eli Lilly USD 3.58B 205M 2026-03
Halozyme Therapeutics USD 108.75M 6.6M 2026-03
Insmed USD 49.5M 3.34M 2026-03
Karyopharm Therapeutics USD 1.48M 35.95M 2025-12
MacroGenics USD 10.12M 34.18M 2025-12
MannKind USD 39.58M 5.94M 2026-03
Merck USD 2.94B 380M 2026-03
Minerva Neurosciences 386K 31K 2024-06
Novavax USD 22.1M 608K 2025-12
Novo Nordisk DKK 1.95B 10.94B 2025-06
Pfizer USD 4.59B 1.7B 2026-03
Sanofi EUR 3.67B 621M 2026-03
Xencor USD 61.66M 50.95M 2025-06